Stallion India Fluorochemicals Ltd

The transcript does not specifically mention current or expected order book or pending orders in detail. However, key points related to orders and capex include: - Orders for most equipment (tank manufacturers, pumps) have already been placed with 20-30% advance payments; balance payments are scheduled upon delivery and commissioning. - Capex utilization appears low currently due to payment stagger but will accelerate as materials arrive by June. - No explicit mention of outstanding orders or order book value was provided. - The company expects strong internal PAT generation and has access to a Rs 120 crore overdraft facility if needed, indicating financial flexibility to support order execution. - They have not entered into pre-contracts for R-32 sales yet, preferring to avoid price-detrimental agreements before production starts. - Focus remains on ramping up production and converting capacities into sales rather than discussing pending order book specifics.

- The company does not envisage any further dilution or equity fundraising going forward, as current revenue and projected PAT generation should suffice for funding needs. (Page 12) - There is no plan to raise additional debt either; working capital is expected to be managed internally through PAT generation and existing bank overdraft/credit facilities (120 crore OD available but largely unutilized). (Page 7) - Current capex is being funded through existing cash balances and rights issue proceeds; payments are staged based on project progress to optimize cash flow. (Page 7) - Overall, no new fundraising through debt or equity is anticipated beyond the existing measures, given the company's conservative financial management and growth plans. (Pages 7, 12)

- Bhilwara HFO plant: Capex of around INR 200 crore (pure plant and machinery) as per government MOU; total capex likely around INR 400 crore. Commissioning targeted by October 2026. - R-32 manufacturing facility: 10,000 metric ton capacity coming online; expected to start production by October, contributing significantly to revenue in FY27. - Mumbattu facility expansion: Scaled up to a 12-tank facility to cover next 10 years; operational by August. - Khalapur helium plant: Near completion, expected to start operations soon. - HFO manufacturing plant: Planned post stabilization of Bhilwara plant, likely after mid-2027; capex range previously mentioned as INR 250 crore in current year and INR 500+ crore next year—conservative estimates. - Continuous expansion approach: One project at a time, stabilization before next, aiming for sustained growth over next 5-7 years. - No further dilution or fundraise expected beyond current capex; internal PAT generation expected to fund working capital requirements.

- Stallion India Fluorochemicals targets a revenue growth CAGR of 30-35% over the next three years. - Current turnover is around INR 430 crores with a PAT of INR 40 crores. - With the R-32 plant becoming fully operational, turnover is expected to cross INR 1100-1200 crores, with PAT around INR 180 crores. - The HFO plant becoming operational will further boost revenues and profits. - The company expects continuous expansion with one project stabilizing before starting the next. - Long-term target by 2030 is INR 3000 crore revenue and INR 500 crore PAT. - Demand for refrigerants and air-conditioning in India is expected to grow 10-15% annually for the next 10 years. - The semiconductor industry is a promising growth driver, with commercial contribution anticipated once helium facility starts (expected June). - Market expansion is focused both domestically and in exports given global capacity deficits.

- Target revenue by 2030: INR 3,000 crore with PAT of INR 500 crore. - Current turnover: INR 430 crore and INR 40 crore PAT. - With full operation of R-32 facility, turnover expected to cross INR 1,100-1,200 crore with ~INR 180 crore PAT. - HFO plant commencement to further boost revenues and profits post stabilization. - Projected 30-35% CAGR revenue growth over the next 3-4 years supported by new plants and expansions. - FY27 PAT expected around INR 100 crore with margins improving in H2 as manufacturing ramps up. - Continuous sequential project commissioning planned every 6 months to ensure steady earnings growth. - Specialty gases and semiconductor industry exposure expected to contribute significantly in long term. - Margin improvement of 3-4% targeted alongside revenue growth due to product mix and operational efficiencies.